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Thiopurines are widely used as antileukemia agents and immunosuppressants. Recent 2 
large-scale clinical studies revealed a strong association between the NUDT15 3 
p.Arg139Cys (NUDT15R139C) polymorphism and severe thiopurine-induced leukocytopenia. 4 
We established knock-in mice harboring p.Arg138Cys (Nudt15R138C), which corresponds to 5 
the human polymorphism. A clinically relevant dose of mercaptopurine (MP) induced lethal 6 
cytopenia in Nudt15R138C-harboring mice. MP dose reduction attenuated the hematopoietic 7 
toxicity, phenocopying clinical observations and providing Nudt15 genotype-based 8 
tolerable doses of MP. High-dose MP induced acute damage to hematopoietic stem and 9 
progenitor cells (HSPCs) in Nudt15R138C/R138C mice. A competitive transplantation assay 10 
revealed that not only Nudt15R138C/R138C HSPCs, but also Nudt15+/R138C HSPCs suffered 11 
stronger damage than Nudt15+/+ HSPCs, even by lower-dose MP, after long-term 12 
administration. In a Nudt15 genotype-based posttransplantation leukemia recurrence model 13 
generated by bone marrow replacement with congenic wild-type cells and a small number 14 
of leukemia stem cells, MP prolonged the survival of mice with posttransplantation 15 
Nudt15R138C/R138C leukemia recurrence. In conclusion, our model will facilitate NUDT15 16 
genotype-based precision medicine by providing safer estimates for MP dosing, and our 17 
4 
 
findings highlighted the high susceptibility of hematopoietic stem cells to MP and 1 
suggested that exploiting thiopurine toxicity might be a novel treatment approach for 2 
leukemia in NUDT15R139C-harboring patients. 3 




Thiopurines are classical drugs that are widely used as cytotoxic agents for many cancers1, 2 2 
and as immunosuppressants for autoimmune or inflammatory diseases3. Mercaptopurine 3 
(MP) plays an important role in maintenance therapy for acute leukemia to achieve 4 
long-term remission4, 5. Azathioprine remains a key drug for inducing and maintaining 5 
remission of inflammatory bowel disease (IBD), although many novel agents have been 6 
developed6. However, patients are frequently forced to reduce or cease thiopurines because 7 
of toxicity, particularly, myelosuppression7.  8 
Thiopurines are enzymatically converted to thio-guanine nucleotides (TGNs), 9 
comprising thio-guanosine-5'-triphosphate (TGTP), thio-guanosine-5'-diphosphate (TGDP), 10 
and thio-guanosine-5'-monophosphate (TGMP)8. TGTP is an active thiopurine metabolite 11 
that can exert cytotoxicity by incorporation into RNA or DNA directly or after further 12 
conversion to thio-deoxyguanosine-5'-triphosphate (TdGTP), respectively9, 10. On the other 13 
hand, TGMP is detoxified by conversion to inactive metabolites by thiopurine 14 
S-methyltransferase (TPMT)11, 12. Single-nucleotide polymorphisms (SNPs) in TPMT have 15 
been reported to attenuate TPMT enzymatic activity and lead to the accumulation of excess 16 
TGNs, inducing predisposition to hematopoietic thiopurine toxicity13-15. However, recent 17 
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retrospective studies have shown that SNPs in TPMT are not significantly associated with 1 
leukocytopenia in Japanese IBD patients16-18.  2 
Recently, we and other groups have identified a nonsynonymous SNP in the 3 
nucleoside diphosphate-linked moiety X-type motif 15 gene (NUDT15), rs116855232 4 
(c.415C>T), as a strong risk factor of thiopurine-induced severe leukopenia in patients with 5 
IBD and pediatric acute lymphoblastic leukemia17-22. NUDT15 is a nucleotide 6 
diphosphatase that can convert TGTP to TGMP and is thus responsible for the inactivation 7 
of thiopurine metabolites; therefore, NUDT15 functions as a negative regulator of cytotoxic 8 
effects10. The c.415C>T SNP induces a p.Arg139Cys (R139C) amino acid change. The 9 
allele with this SNP (termed NUDT15R139C hereafter) is present in approximately 25% of 10 
the Japanese population18 and 20% of the East Asian population20. NUDT15 R139C likely 11 
has lost enzyme activity in vivo because of the negative influence of this SNP on protein 12 
stability and loss of catalytic efficiency10, 20. Other SNPs in NUDT15 causing p.Arg139His, 13 
p.Val18Ile, p.Val18_Val19insGlyVal, p.Arg34Thr, p.Lys35Glu, p.Gly17_Val18del, 14 
p.Met1Thr, and p.Gly47Arg have also been uncovered18, 20. The allele encoding 15 
p.Val18_Val19insGlyVal is the second most frequent and co-occurs with R139C in most 16 
cases. Other SNPs are present at very low frequency and appear to attenuate catalytic 17 
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efficiency. Finally, according to a large retrospective study in Japanese IBD patients, the 1 
NUDT15R139C allele has a significant impact on thiopurine-induced leukopenia, as the odds 2 
ratio for severe leukopenia is 13.4 and 807 in R139C heterozygous patients and 3 
homozygous patients, respectively18. Therefore, thiopurine administration requires 4 
precision medicine based on the NUDT15 genotype. 5 
To achieve precision medicine, a physiological model to estimate the tolerable 6 
thiopurine doses and thoroughly investigate the mechanism of hematopoietic system 7 
damage is needed. Although a Nudt15 knock-out mouse model was recently established23, 8 
it is unclear whether complete loss of Nudt15 is equivalent to the protein instability or 9 
catalytic efficiency loss induced by R139C, as two recent papers reported conflicting 10 
results; Valerie et al. reported that R139C influences protein stability, but not catalytic 11 
efficacy, whereas Moriyana et al. reported opposite findings10, 20. In addition, tolerable 12 
doses of thiopurines in heterozygous mice have not been addressed, although NUDT15R139C 13 
heterozygous patients frequently suffer from leukopenia18, 24. Further, it remains unclear 14 
how NUDT15 R139C affects the susceptibility of hematopoietic stem and progenitor cells 15 
(HSPCs) to thiopurines, although severe HSPC damage directly causes critical adverse 16 
effects, especially in leukemia treatment. In the current study, we address these unresolved 17 
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issues by generating a more physiologically relevant mouse model of human NUDT15 1 
R139C, i.e., a knock-in mouse model harboring a c.412C>T allele in the murine Nudt15 2 
coding region (termed Nudt15R138C hereafter) that causes the p.Arg138Cys (R138C) 3 
substitution. 4 
 5 
  6 
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Materials and methods 1 
Mice 2 
C57BL/6 and C57BL/6-Ly-5.1 mice were obtained from Charles River Laboratories Japan 3 
(Yokohama, Japan) or CLEA Japan, Inc. (Tokyo, Japan), and the RIKEN BioResource 4 
Center (Tsukuba, Japan), respectively. To generate Nudt15+/R138C mice, single-guide 5 
(sg)RNAs were designed to target near c.412 in the coding sequence of mouse Nudt15 (Fig. 6 
1a) using the optimized CRISPR design tool provided by the Zhang lab 7 
(http://crispr.mit.edu/)25. One hundred-twenty-base pair donor oligoDNAs with c.412C>T 8 
in the center were created for homology-directed repair (Supplementary Table 1). Zygotes 9 
from C57BL/6 mice received coinjection of sgRNAs (5 ng/μl) and oligoDNAs (100 ng/μl) 10 
and were transferred into the oviducts of pseudopregnant female mice. Based on 11 
sequencing analysis (primers shown in Supplementary Table 1), F0 generation mice that 12 
harbored Nudt15 c.412C>T, but not the Cas9 gene from the gene editing system nor 13 
mutations in the pseudogenes Gm13534 and Gm5919 with the same sequence as sgRNA 14 
targets, were selected and bred with wild-type C57BL/6 mice. Two F1 generation mice 15 
were reconfirmed to exhibit transmission of the Nudt15 c.412C>T allele and were named 16 
strain 69 and strain 115, respectively. For analyses, 7- to 12-week-old littermates from 17 
10 
 
breeding pairs from the Nudt15+/R138C F2, F3, and F4 generations were used. Generation 1 
and selection of F0 mice were carried out at TransGenic Inc. (Fukuoka, Japan). All mice 2 
after F1 generations were maintained under specific pathogen-free conditions at the 3 
Research Center for Animal Life Science of Shiga University of Medical Science. All 4 
animal experiments were approved by the Animal Research Committee of Shiga University 5 
of Medical Science. 6 
 7 
Fluorescence-activated cell sorting (FACS) analysis 8 
Peripheral white blood cells and bone marrow (BM) cells were stained with the antibodies 9 
indicated in each experiment after brief lysis of erythrocytes by 10 
ammonium-chloride-potassium buffer. We used antibodies directed against CD3e 11 
[145-2C11], CD4 [GK1.5], CD8a [53-6.7], CD19 [6D5], Mac1 [M1/70], Gr-1 [RB6-8C5], 12 
B220 [RA3-6B2], Ter119 [TER-119], Ly-6G [1A8], CD34 [RAM34], CD16/32 [93], 13 
CD135 [A2F10], c-kit [2B8], and Sca-1 [D7]. To distinguish donor cells from competitor 14 
and recipient cells, the cells were also stained with anti-CD45.1 [A20] and anti-CD45.2 15 
[104] antibodies. Ly-6G+MAC-1+, B220+CD3e–, and B220–CD3e+ cells were defined as 16 
neutrophils, B lymphocytes, and T lymphocytes, respectively. Lineage markers used in 17 
11 
 
analysis of HSPCs included CD3e, CD4, CD8a, CD19, Mac1, Gr-1, B220 and Ter119. 1 
Each HSPC population was defined as described elsewhere26, 27; hematopoietic stem cells 2 
(HSCs; CD34–/lowFlt3–Lineage–Sca-1+c-Kit+), multipotent progenitors (MPPs; CD34+Flt3–3 
Lineage-Sca-1+c-Kit+), lymphoid-primed multipotent progenitors (LMPPs; 4 
CD34+Flt3+Lineage–Sca-1+c-Kit+), common myeloid progenitors (CMPs; Lineage–5 
Sca-1+c-Kit+CD16/32lowCD34low), granulocyte-monocyte progenitors (GMPs; Lineage–6 
Sca-1+c-Kit+CD16/32+CD34+), and megakaryocyte-erythrocyte progenitors (MEPs; 7 
Lineage–Sca-1+c-Kit+CD16/32–CD34–). The antibodies were purchased from eBioscience 8 
(San Diego, CA, USA), BD Biosciences (San Jose, CA, USA), or BioLegend (San Diego, 9 
CA, USA). Flow-cytometric data were acquired using a FACSCantoTM II or FACSAria (BD 10 
Biosciences) and were analyzed using the FACSDiva and FlowJo (BD Biosciences) 11 
software. 12 
 13 
MP administration and toxicity analyses 14 
MP (Sigma, St. Louis, MO, USA) was orally administered as described elsewhere28, 29. As 15 
mice drink approximately 5 ml daily according to a previous report30 and our observations, 16 
MP-containing water was adjusted to 0.4 μg MP × mouse body weight (g) × ml–1 for the 17 
12 
 
administration of 2 mg/kg MP. Drinking bottles were exchanged every three days. Control 1 
mice were given drinking water containing the same amount of DMSO. Peripheral blood 2 
counts were determined with Celltacα (Nihon Koden, Tokyo, Japan). Differential leukocyte 3 
counts were determined by multiplying the number of WBCs by the percentage of each 4 
population. For BM histology, formalin-fixed femurs were decalcified with K-CX (FALMA, 5 
Tokyo, Japan) according to the manufacturer’s procedure and sectioned. 6 
 7 
Competitive transplantation and chimerism analysis 8 
Two million BM cells from Nudt15+/+, Nudt15+/R138C, or Nudt15R138C/R138C mice (Ly5.2+) 9 
and from age-matched C57BL/6-Ly5.1 mice (Ly5.1+) were transplanted into lethally 10 
irradiated (10.5 Gy) age-matched recipient mice (Ly5.1+Ly5.2+) that were generated by 11 
breeding C57BL/6 and C57BL/6-Ly5.1 mice. Chimerism in each population was calculated 12 
as the ratio of targeted donor cells (Ly5.1–Ly5.2+) to competitor cells (Ly5.1+Ly5.2–). 13 
 14 
Leukemia model 15 
MLL-AF9 retrovirus-containing supernatant was generated and transduced into Lineage–16 
c-Kit+ cells from BM cells of Nudt15+/+, Nudt15+/R138C, or Nudt15R138C/R138C mice as 17 
13 
 
described previously26, 31. To develop leukemic mice, after culture in viral-free medium, 1 
MLL-AF9-transduced cells were transplanted into congenic C57BL/6-Ly5.1 mice after 2 
6-Gy sublethal irradiation. Leukemia stem and progenitor cells were purified as the 3 
Ly5.2+Lineage–c-Kit+ population from the BM of leukemic mice32, 33. To establish a 4 
posttransplantation leukemia recurrence model, 5 000 or 250 leukemia stem and progenitor 5 
cells and 2 × 106 BM cells from congenic C57BL/6-Ly5.1 mice were transplanted into 6 
concordant Nudt15 genotype mice after 10.5-Gy lethal irradiation. The mice were 7 
euthanized when they became moribund for analysis of chimerism and cytology. 8 
 9 
Cytology 10 
Cells (1–5 × 104) were suspended in phosphate-buffered saline and attached to glass slides 11 
by centrifugation at 800 rpm for 4 minutes using Cytospin 4 (Thermo, Waltham, MA, USA). 12 
The glass slides were stained with a traditional Wright-Giemsa staining. 13 
 14 
Statistical analysis 15 
ANOVA followed by Tukey’s tests was adopted for multiple comparison analyses of 16 
toxicity and hematopoiesis among mouse genotypes. The Kaplan Meier test was adopted 17 
14 
 
for survival analyses. All analyses were conducted in GraphPad Prism version 6 (GraphPad 1 
software, La Jolla, CA, USA). All tests were two-sided, and a p-value <0.05 was 2 





Establishment of knock-in mice harboring the Nudt15R138C allele 2 
The human and murine NUDT15 proteins share 89% sequence identity. The arginine 3 
residue at position 139 of human NUDT15 is conserved at position 138 of murine Nudt15 4 
(Supplementary Figure 1). Overexpression of the murine Nudt15 R138C mutant enhanced 5 
susceptibility to MP in a murine blood cell line (Supplementary Figure 2). Thus, we newly 6 
established knock-in mice harboring the Nudt15R138C allele on the C57BL/6 background by 7 
converting c.412 C to T utilizing CRISPR-CAS9 genome editing and homology-directed 8 
repair (Fig. 1a). Using two different sgRNAs to minimize off-target effects caused by 9 
sgRNAs, we generated two independent F0 mice, mouse number 115 and mouse number 69, 10 
that harbored the Nudt15R138C allele. By crossing the two F0 mice to wild-type C57BL/6 11 
mice, we generated F1 mice that inherited the Nudt15R138C allele, but did not harbor 12 
mutations in the two pseudogenes Gm13534 and Gm5919, which have the same sequence 13 
as the sgRNA targets (Supplementary Figure 3), and we termed them strain 115 and strain 14 
69. Finally, Nudt15+/+, Nudt15+/R138C, and Nudt15R138C/R138C mice were viably generated by 15 
mating Nudt15+/R138C mice (Fig. 1b) in a Mendelian fashion, and these mice exhibited no 16 
differences in appearance. Next, we assessed transcript and protein levels of Nudt15 in each 17 
16 
 
genotype mouse and found no difference between wild-type Nudt15 and Nudt15 R138C. 1 
This data indicates that intrinsic expression of Nudt15 R138C does not influence protein 2 
stability (Supplementary Figure 4a/b). Furthermore, we measured TGMP after incubation 3 
of TGTP with extract from packed red blood cells collected from Nudt15+/+ or 4 
Nudt15R138C/R138C mice. TGMP production was reduced by approximately 35% in 5 
Nudt15R138C/R138C mice compared to Nudt15+/+ mice, indicating that R138C partially, but 6 
not completely, impairs the enzyme activity of Nudt15.   7 
 8 
Nudt15+/R138C and Nudt15R138C/R138C mice are highly susceptible to MP 9 
To evaluate the association of Nudt15 R138C with thiopurine toxicity, Nudt15+/+, 10 
Nudt15+/R138C, and Nudt15R138C/R138C mice were orally administered MP at 0.2, 1, or 2 11 
mg/kg daily, which is equivalent to the clinical dose. In the 2 mg/kg MP arm, 12 
Nudt15R138C/R138C mice exhibited early death (median survival of 15 days and 21 days in 13 
strains 115 and 69, respectively) (Fig. 2a/b; p < 0.0001 by log-rank test in both strains). 14 
Nudt15+/R138C mice also died earlier than Nudt15+/+ mice, although their median survival 15 
time was approximately twice as long as that of Nudt15R138C/R138C mice (median survival of 16 
30 days in both strains 115 and 69). By reducing the MP dose to 1 mg/kg, the survival time 17 
17 
 
of Nudt15R138C/R138C mice and Nudt15+/R138C mice was prolonged by up to twofold (median 1 
survival of 26 days and 66 days, respectively, in strain 115, and 21 days and 48 days, 2 
respectively, in strain 69). Upon administration of 0.2 mg/kg MP, all mice survived longer 3 
than 70 days. These data indicated that Nudt15R138C-harboring mice exhibit high 4 
susceptibility to MP, with susceptibility depending on the MP dose and the number of 5 
Nudt15R138C alleles. 6 
 7 
MP induces cytopenia in Nudt15+/R138C and Nudt15R138C/R138C mice 8 
To evaluate hematological toxicity, we determined peripheral blood cell counts every week 9 
after starting MP administration. Nudt15R138C/R138C mice exhibited severe pancytopenia 14 10 
days after starting 2 mg/kg MP orally (Fig. 3a and Supplementary Figure 6a). Nudt15+/R138C 11 
mice also showed pancytopenia, to the midpoint level between Nudt15+/+ and 12 
Nudt15R138C/R138C mice. Pancytopenia was alleviated by reducing the MP dose to 1 mg/kg 13 
and was hardly observed upon administration of 0.2 mg/kg MP for 70 days. Next, we 14 
conducted differential counts of leukocytes, including neutrophils, T lymphocytes, and B 15 
lymphocytes, by FACS analysis (Fig. 3b). Especially, neutrophils were moderately or 16 
severely depleted in Nudt15+/R138C mice or Nudt15R138C/R138C mice, respectively, after 17 
18 
 
administration of 2 mg/kg MP for 14 days (Fig. 3c and Supplementary Figure 6b). Severe 1 
neutropenia was observed in Nudt15R138C/R138C mice after 1 or 2 mg/kg MP administration 2 
for 7 days, but not after 0.2 mg/kg MP administration for 70 days. These data clearly 3 
indicated that our mouse model phenocopies the clinical observations of severe or moderate 4 
acute leukopenia in NUDT15R139C homozygous patients or heterozygous patients, 5 
respectively, and that dose reduction relieves the hematologic toxicity of MP. 6 
 7 
MP rapidly impairs HSPCs in Nudt15R138C/R138C mice 8 
The rapid occurrence of neutropenia and anemia at high doses of MP predicts the 9 
development of BM suppression. Thus, we investigated BM histology in the steady state 10 
and after treatment with 5 mg/kg MP for 5 days. HE staining revealed no histological 11 
differences among mice with different genotypes in the steady state (Supplementary Figure 12 
7a), but we observed severe decreases in nucleated BM cells in Nudt15R138C/R138C mice after 13 
MP exposure (Fig. 4a). Similarly, HSCs, uncommitted hematopoietic progenitor cells 14 
(HPCs) including MPPs and LMPPs, and myeloid-committed HPCs, including CMPs, 15 
GMPs, and MEPs, were stored in all genotypes in the steady state (Supplementary Figure 16 
7b), whereas the frequencies of HSCs, LMPPs, CMPs, GMPs, and MEPs were significantly 17 
19 
 
decreased in Nudt15R138C/R138C mice after oral administration of 2 mg/kg MP for 5 days (Fig. 1 
4b/c). Although MP is also known to exert toxicity to organs other than BM13, 18, no gross 2 
abnormalities were observed in other organs, including the esophagus, stomach, intestines, 3 
liver, lungs, and kidneys, after administration of 5 mg/kg MP (Supplementary Figure 8). 4 
These data suggest that both HSCs and HPCs can be impaired at clinically relevant doses of 5 
MP in NUDT15R139C homozygous patients. 6 
 7 
Nudt15+/R138C and Nudt15R138C/R138C HSPCs are exhausted after long-term exposure to 8 
low-dose MP 9 
We investigated the tolerance of Nudt15+/R138C and Nudt15R138C/R138C HSPCs to long-term 10 
exposure to a low dose of MP. To enable precise comparison with wild-type HSCs, a 11 
competitive transplantation method was adopted. Briefly, BM cells from Nudt15+/+, 12 
Nudt15+/R138C, or Nudt15R138C/R138C mice (Ly5.2-positive) were transplanted with the same 13 
number of BM cells from congenic mice (Ly5.1-positive) into recipient mice (Ly5.1- and 14 
Ly5.2-positive), which were orally treated with various doses of MP from 5 weeks after 15 
transplantation (Supplementary Figure 9). Peripheral leukocytes and BM cells were 16 
analyzed by FACS to assess the chimeric state, which was calculated as the ratio of 17 
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Ly5.2-positive donor cells to Ly5.1-positive competitor cells. Neutrophil chimerism 1 
analysis showed that Nudt15R138C/R138C neutrophils were nearly completely depleted by day 2 
14 after starting administration of 1 or 2 mg/kg MP (Fig. 5a and Supplementary Figure 10). 3 
Even in the case of 0.2 mg/kg MP, the chimeric ratio in Nudt15R138C/R138C neutrophils 4 
decreased to approximately half of that in Nudt15+/+ neutrophils after administration for 28 5 
days. Half or complete depletion of Nudt15+/R138C neutrophils was also observed after 6 
administration of 1 mg/kg MP for 14 or 28 days, respectively. HSPC chimerism analysis 7 
revealed that Nudt15R138C/R138C uncommitted HSPCs, such as Lineage–Sca-1+c-Kit+ cells 8 
(LSKs), and myeloid-committed progenitors, such as CMPs and GMPs, were completely 9 
depleted after administration of 1 mg/kg MP for 28 days (Fig. 5b and Supplementary Figure 10 
11). Even when the MP dose was reduced to 0.2 mg/kg, all Nudt15R138C/R138C HSPC 11 
fractions were depleted by more than 70%. In Nudt15+/R138C HSPC fractions, nearly 12 
complete or approximately half depletion was observed after administration of 1 mg/kg MP 13 
or 0.2 mg/kg MP, respectively, for 28 days. Finally, we calculated the reduction rate of each 14 
Nudt15+/R138C or Nudt15R138C/R138C HSPC fraction to the corresponding congenic wild-type 15 
HSPC fraction (Fig. 5c). The MP dose required for a 50% reduction was 0.23 or 0.12 16 
mg/kg in Nudt15+/R138C LSKs or Nudt15R138C/R138C LSKs, respectively, 0.19 or 0.099 mg/kg 17 
21 
 
in Nudt15+/R138C CMPs or Nudt15R138C/R138C CMPs, respectively, and 0.23 or 0.11 mg/kg in 1 
Nudt15+/R138C GMPs or Nudt15R138C/R138C GMPs, respectively. These data suggested that 2 
Nudt15+/R138C HSPCs can tolerate twice the amount of MP tolerated by Nudt15R138C/R138C 3 
HSPCs, but they may be seriously damaged after long-term administration of relatively 4 
low-dose MP.  5 
 6 
MP impairs Nudt15+/R138C or Nudt15R138C/R138C leukemia cells in a posttransplantation 7 
leukemia recurrence model 8 
We examined whether MP could be a possible option for NUDT15R139C homozygous 9 
patients with hematopoietic malignancies by exploiting the high susceptibility to MP. To 10 
this end, we generated a posttransplantation leukemia recurrence model by applying the 11 
MLL-AF9 leukemia model32, 33. Briefly, 5 000 Nudt15+/+ or Nudt15R138C/R138C leukemia 12 
stem and progenitor cells (Ly5.2+Lineage–Kit+) were sorted from mice that had developed 13 
leukemia by transplantation of MLL-AF9-transduced cells, and were transplanted into 14 
genotypically concordant mice together with two million normal BM cells from congenic 15 
mice. In these mice, peripheral blood was dominated by cells (Ly5.1+Ly5.2–) derived from 16 
congenic BM cells two weeks after transplantation, but by recipient phenotype cells (Ly5.1–17 
22 
 
Ly5.2+) approximately four weeks after transplantation, and the mice exhibited 1 
splenomegaly due to leukemic cell infiltration (Fig. 6a). Therefore, these mice reflect 2 
patients who experience leukemia relapse after transplantation from a NUDT15 wild-type 3 
donor. The mice were randomly assigned to a control arm and an MP arm on day 15 after 4 
transplantation. In the control arm orally administered vehicle, posttransplantation 5 
Nudt15+/+ and Nudt15R138C/R138C leukemia recurrence mice died due to leukemia 6 
development within 30 days after transplantation (Fig. 6a). Oral administration of 1 mg/kg 7 
MP significantly prolonged the survival of posttransplantation Nudt15R138C/R138C leukemia 8 
recurrence mice (median: 21 days vs. 34 days in control vs. MP, p = 0.0002), but not 9 
posttransplantation Nudt15+/+ leukemia recurrence mice (median: 26 days vs. 26 days in 10 
control vs. MP). These data demonstrated that support by normal wild-type hematopoiesis 11 
allows the administration of a lethal dose of MP for Nudt15+/+ mice and that the difference 12 
in susceptibility to MP between Nudt15R138C/R138C leukemia cells and wild-type normal 13 
donor HSPCs can be exploited for leukemia treatment. Moreover, to evaluate the effect of 14 
early intervention, we transplanted a smaller number of leukemia stem and progenitor cells 15 
and analyzed spleens 12 days after starting administration. Splenomegaly due to leukemic 16 
cell infiltration was suppressed by administration of 1 mg/kg MP in posttransplantation 17 
23 
 
Nudt15R138C/R138C leukemia recurrence mice (Fig. 6b). The survival time of 1 
posttransplantation Nudt15R138C/R138C leukemia recurrence mice was prolonged in the MP 2 
arm (median: 40 days vs. 63 days in control vs. MP, p = 0.0002). These data suggested that 3 





We generated Nudt15R138C knock-in mice that exhibit thiopurine-mediated cytopenia in a 2 
Nudt15R138C allele number-dependent manner, which is alleviated by reducing the dose of 3 
MP. The enzyme activity involved in thiopurine metabolism is known to vary across races. 4 
Particularly, TPMT enzyme activity is reported to be lower in Japanese patients than in 5 
Caucasians34-37. This may reduce the impact of TPMT and explains why an association 6 
between TPMT SNPs and leukopenia is found in Caucasians, but not Japanese patients. 7 
Similarly, TPMT enzyme activity varies across mouse backgrounds38, 39. Therefore, to more 8 
precisely reflect the patient background, we aimed to establish a physiological knock-in 9 
mouse model with relatively low TPMT enzyme activity. In this context, we established 10 
Nudt15R138C knock-in mice in the C57BL/6 background with low TPMT activity, not in the 11 
FVB/N background, which exhibits high TPMT activity and is adopted in the Nudt15 12 
knock-out mouse model. Finally, our model showed no failure in any organ other than the 13 
BM; we did not find esophagus injury, which is observed in Nudt15 knock-out mice23, nor 14 
hepatotoxicity, which is frequently caused by thiopurines and significantly associated with 15 
TPMT SNPs13, 18. In addition, our model successfully provided safer estimates of MP dose 16 
for NUDT15R139C homozygous or heterozygous patients. Nudt15R138C/R138C mice survived 17 
25 
 
for at least 70 days when orally administered 0.2 mg/kg MP. A dose of 0.2 mg/kg in mice is 1 
equivalent to approximately 0.016 mg/kg in an adult human40. This estimate clearly 2 
supports the previous report that 1–2 mg per whole body was estimated as a safer initial 3 
daily dose of MP for NUDT15R139C homozygous adult patients18. Furthermore, although the 4 
susceptibility to MP in Nudt15+/– mice was not reported23, in our study, half of the 5 
Nudt15+/R138C mice exhibited late-onset death at 1 mg/kg MP, suggesting that it is 6 
presumably safer to start treatment at 0.08 mg/kg or less in NUDT15R139C heterozygous 7 
adult patients. Together, these findings indicate that our model sufficiently phenocopies 8 
thiopurine-induced myelosuppression in patients with the NUDT15R139C allele to contribute 9 
to NUDT15 genotype-based precision medicine. 10 
Our data indicated that not only HPCs, but also HSCs were impaired in 11 
Nudt15R138C/R138C mice treated short-term with a clinically relevant dose of MP, implying 12 
that HSCs suffer acute MP damage in NUDT15R139C homozygous patients. Previous reports 13 
demonstrated that NUDT15 R139C or loss of Nudt15 enhanced thiopurine-induced 14 
cytotoxicity20, 23, but did not clarify whether HSPCs with the SNP allele were more severely 15 
impaired by thiopurines. As HPCs are highly proliferative whereas HSCs are generally 16 
dormant, cytotoxic agents that act during DNA synthesis can rapidly injure HPCs, but 17 
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require a longer time to impair HSCs41, 42. Therefore, acute damage of Nudt15R138C/R138C 1 
HSCs by MP may be caused in a cell cycle-independent manner. Further studies will be 2 
needed to clarify the mechanism underlying the acute damage in Nudt15R138C/R138C HSCs 3 
and the alterations of thiopurine metabolism. On the other hand, our competitive 4 
transplantation assay demonstrated that LSKs, which include HSCs and uncommitted 5 
progenitors, were impaired by long-term administration of low-dose MP. The MP dose for a 6 
50% reduction in Nudt15+/R138C or Nudt15R138C/R138C LSKs was 0.23 mg/kg or 0.12 mg/kg, 7 
respectively, which was equivalent to that in genotypically concordant CMPs and GMPs. It 8 
is known that the majority of HSCs exit the G0 phase and enter the cell cycle in response to 9 
long-term BM injury by a cytotoxic agent, such as 5-fluorouracil42. As cycling HSCs 10 
become sensitive to cytotoxic agents, long-term exposure of MP could lead to Nudt15+/R138C 11 
or Nudt15R138C/R138C HSC damage, even at low doses. Together, our data suggest that MP 12 
should be carefully administered to NUDT15R139C heterozygous or homozygous patients in 13 
long-term maintenance therapy. 14 
We established a Nudt15 genotype-based posttransplantation leukemia recurrence 15 
model. In this model, BM of Nudt15+/+ or Nudt15R138C/R138C mice was replaced with normal 16 
wild-type BM cells from congenic mice and a small number of genotypically concordant 17 
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MLL-AF9 leukemia stem and progenitor cells. Consequently, these mice died due to 1 
leukemia development after acquiring the engraftment of normal BM-cells dominance, 2 
reflecting leukemia recurrence after transplantation from a NUDT15 wild-type donor. 3 
However, MP significantly prolonged the survival of mice with posttransplantation 4 
Nudt15R138C/R138C leukemia recurrence. Furthermore, lethal doses of MP for 5 
Nudt15R138C/R138C mice were tolerable upon normal wild-type hematopoiesis. A previous 6 
study using a different leukemia model based on combination of Arf–/– and BCR-ABL1 7 
reported that MP might be administrable in Nudt15–/– leukemia mice23; however, safety has 8 
remained a major issue because the observation period was too short. In fact, several 9 
reports have referred to the impossibility of MP administration to safely treat leukemia 10 
patients with NUDT15 R139C20, 43. In addition, the high susceptibility of Nudt15+/R138C or 11 
Nudt15R138C/R138C HSCs to low-dose MP implies that MP does not preferentially kill 12 
leukemia cells and consequently, might eliminate HSCs impaired by leukemia. Together, 13 
our data indicate that NUDT15-based thiopurine myelotoxicity can be safely and 14 
maximally exploited in leukemia treatment with the support of normal wild-type HSCs in 15 
NUDT15R139C-harboring patients. Further clinical studies are warranted to investigate 16 
whether MP is effective for NUDT15R139C heterozygous or homozygous leukemia patients 17 
28 
 
who have recurrence or a high risk of relapse after allogenic hematopoietic stem cell 1 
transplantation from NUDT15 wild-type donors. 2 
In conclusion, our novel Nudt15R138C knock-in mouse model provided safer 3 
estimates for MP dosing and highlighted the high susceptibility of HSPCs to MP. The 4 
conceptual finding that NUDT15 genotype-based hematopoietic toxicity caused by MP can 5 
be converted to a leukemia treatment is expected to contribute to the development of novel 6 
leukemia treatments. Finally, our model will facilitate NUDT15 genotype-based precision 7 
medicine for patients receiving thiopurines. 8 
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Figure legends 1 
Fig. 1.  2 
Establishment of Nudt15R138C harboring mice. 3 
(A) Schematic diagram of the establishment of mice harboring the Nudt15R138C allele by 4 
gene editing. The target sites of different sgRNAs for strain 69 and strain 115 and the donor 5 
oligoDNA for converting c.412 C to T are indicated. (B) Validation of Nudt15 c.412 C>T 6 
by sequencing in strains 115 and 69. The base at c.412 is indicated in red.  7 
 8 
Fig. 2.  9 
Overall survival of Nudt15+/+, Nudt15+/R138C, and Nudt15R138C/R138C mice upon MP 10 
administration. 11 
OS upon oral administration of 0.2, 1, or 2 mg/kg MP in strain 115 (top) and in strain 69 12 
(bottom). In each arm, 7–11 mice were analyzed. The treatment and observation period was 13 
70 days. p < 0.0001 for both strains (log-rank test). 14 
 15 
Fig. 3.  16 
MP enhances cytopenia in Nudt15+/R138C and Nudt15R138C/R138C mice.  17 
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(A) Peripheral blood cell counts after oral administration of 2 mg/kg MP for 7 or 14 days, 1 1 
mg/kg MP for 7 or 14 days, or 0.2 mg/kg MP for 14, 28, 42, 56, or 70 days. Data are 2 
presented in box and whiskers with 10 to 90 percentile. Horizontal lines in boxes indicate 3 
the means. (B) Representative FACS plots of neutrophils, B lymphocytes, and T 4 
lymphocytes after oral administration of 2 mg/kg MP for 14 days. Populations and 5 
percentages are indicated by red boxes and in red font, respectively. (C) Summarized data 6 
of the number of neutrophils, B lymphocytes and T lymphocytes. Data are presented in box 7 
and whiskers with 10 to 90 percentile. Horizontal lines in boxes indicate the means. The 8 
data were obtained from strain 115. The data from strain 69 are presented in Supplementary 9 
Figure 6. In (A) and (C), 6–9 mice were analyzed in each group. *p < 0.05, **p < 0.01, 10 
***p < 0.001, and ****p < 0.0001 (ANOVA followed by Tukey’s test).  11 
   12 
Fig. 4.  13 
BM failure in Nudt15R138C/R138C mice after short-term MP treatment. 14 
(A) BM histology after intraperitoneal injection of 5 mg/kg MP. HE staining after 15 
decalcification is presented. The genotype is indicated at the top of the panel. Scale bars 16 
indicate 50 μm. (B) Representative FACS plots of LK (Lineage–Sca-1–c-Kit+), LSK 17 
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(Lineage–Sca-1+c-Kit+), CMP (Lineage–Sca-1+c-Kit+CD16/32lowCD34low), GMP (Lineage–1 
Sca-1+c-Kit+CD16/32+CD34+), MEP (Lineage–Sca-1+c-Kit+CD16/32–CD34–), HSCs 2 
(CD34–/lowFlt3-Lineage–Sca-1+c-Kit+), MPP (CD34+Flt3–Lineage–Sca-1+c-Kit+), and LMPP 3 
(CD34+Flt3+Lineage–Sca-1+c-Kit+). Each population is indicated and labeled by red boxes 4 
and red characters. Two million BM cells were analyzed by FACS after oral administration 5 
of 2 mg/kg MP for 5 days. (C) Summarized data of cell numbers in each HSPC population. 6 
The X- and Y-axis indicate the Nudt15 genotype and the number of cells in each population, 7 
respectively. For each genotype, 5–6 mice were analyzed. *p < 0.05, **p < 0.01, ***p < 8 
0.001, and ****p < 0.0001 (ANOVA followed by Tukey’s test). 9 
 10 
Fig. 5.  11 
HSPC impairment assessed by competitive transplantation assay. 12 
(A) Neutrophil chimerism (Ly-6G+MAC1–). Chimerism was calculated by dividing the 13 
number of Ly5.2+ cells by the number of Ly5.1+ cells. The X-axis indicates the number of 14 
days of administration of MP. The Y-axis indicates the ratio of neutrophil chimerism on 15 
indicated days compared to that on day 0. Mean and SD are presented. Representative 16 
FACS plots are shown in Supplementary Figure 10. (B) Chimerism in LSKs, CMPs, and 17 
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GMPs after MP administration for 28 days. The X-axis indicates the number of MP doses. 1 
The Y-axis indicates the ratio of each HSPC chimerism for indicated MP doses compared to 2 
that for 0 mg/kg. The mean and SD are presented. Representative FACS plots are shown in 3 
Supplementary Figure 11. In each group, 3–5 mice were analyzed. *p < 0.05, **p < 0.01, 4 
***p < 0.001, and ****p < 0.0001 (ANOVA followed by Tukey’s test). (C) The reduction 5 
curves for Nudt15+/R138C or Nudt15R138C/R138C LSKs, CMPs, and GMPs. The X- and Y-axis 6 
indicate the same as in (B). In each group, 2–3 mice were analyzed. The curve was drawn 7 
with GraphPad Prism version 6. 8 
 9 
Fig. 6.  10 
Antileukemic efficacy of MP in posttransplantation Nudt15+/+ or Nudt15R138C/R138C 11 
leukemia recurrence mice.  12 
(A) A posttransplantation Nudt15+/+ or Nudt15R138C/R138C leukemia recurrence mouse model 13 
was generated by injection of 5 000 MLL-AF9 leukemia stem cells and progenitors. In 14 
upper figures, FACS data in the left panels indicate that congenic (Ly5.1+Ly5.2–) cells were 15 
dominant in peripheral blood at 14 days after transplantation, indicating normal BM 16 
engraftment, while recipient phenotype (Ly5.1–Ly5.2+) cells were dominant when mice 17 
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became moribund approximately two weeks later. Right panels present spleen size and 1 
cytology of spleen cells as assessed by Wright–Giemsa staining. Bottom figures present 2 
survival curves of posttransplantation Nudt15+/+ and Nudt15R138C/R138C leukemia recurrence 3 
mice by starting at 1 mg/kg MP or DMSO from day 15. (B) A posttransplantation Nudt15+/+ 4 
or Nudt15R138C/R138C leukemia recurrence mouse model was generated by injection of 250 5 
MLL-AF9 leukemia stem cells and progenitors. Upper figures present spleen size and 6 
FACS plot of spleen cells 12 days after starting 1 mg/kg MP. Bottom figures present 7 
survival curves of posttransplantation Nudt15+/+ and Nudt15R138C/R138C leukemia recurrence 8 
mice by starting 1 mg/kg MP or DMSO from day 15. In each arm, 7–12 mice were 9 
analyzed. p-Values were calculated by the log-rank test. One scale of the ruler indicates 1 10 
mm. 11 
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